Agostina Stradella

Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study

Funda Meric‐Bernstam, Randy F. Sweis, Stefan Kasper et al. · Clinical Cancer Research · 2022 · 205 citations · Full text

Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial

José Manuel Pérez-García, Géraldine Gebhart, Manuel Ruíz Borrego et al. · The Lancet Oncology · 2021 · 152 citations

Breast Oncology, Medicine, Chemotherapy De-escalation +5

LBA15 Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer

C. Saura Manich, Joyce O’Shaughnessy, Philippe Aftimos et al. · Annals of Oncology · 2021 · 103 citations

Metastatic Breast Cancer, Breast Oncology, Medicine +7

A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study

Begoña Martı́n-Castillo, Sònia Pernas, Joan Dorca et al. · Oncotarget · 2018 · 76 citations · Full text

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

José Manuel Pérez-García, Javier Cortés, Manuel Ruíz‐Borrego et al. · The Lancet · 2024 · 69 citations

Breast Oncology, Medicine, Chemotherapy De-escalation +4